Skip to main navigation

About Us
Our Products
Investor Relations
News
Cumberland Emerging Technologies
Blog

About Us
Our Products
Investor Relations
News
Cumberland Emerging Technologies
Blog

Press Releases

Year

Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex

Jul 01, 2026

PDF Version

Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

Jun 26, 2026

PDF Version

Presentation

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Jun 02, 2026

PDF Version

CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA

May 28, 2026

PDF Version

CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE

May 05, 2026

PDF Version

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE

Apr 28, 2026

PDF Version

Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex

Apr 23, 2026

PDF Version

CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE

Apr 16, 2026

PDF Version

Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting

Mar 17, 2026

PDF Version

Cumberland Pharmaceuticals Reports 31% Fourth Quarter 2025 Revenue Growth

Mar 03, 2026

PDF Version

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 23

© 2026 Cumberland Pharmaceuticals, Inc. All Rights Reserved.

Privacy Policy

Accessibility Statement

Terms of Use